This treatment is oral, effective, well tolerated and has proven to be beneficial in patients with GSD1b; however, the effect of the drug in pregnancy remains limited to an n = 1, indicating the need for close monitoring for hypoglycemia, urinary tract infections, hydration status, and renal function. This evidence concerns the gene SLC37A4 and Hypoglycemia.